{"id":1319,"date":"2025-05-27T08:04:07","date_gmt":"2025-05-27T08:04:07","guid":{"rendered":"https:\/\/youdigital.pk\/en\/?p=1319"},"modified":"2025-05-27T08:04:07","modified_gmt":"2025-05-27T08:04:07","slug":"fda-oks-nucala-for-smokers-lung-treatment","status":"publish","type":"post","link":"https:\/\/youdigital.pk\/en\/2025\/05\/27\/fda-oks-nucala-for-smokers-lung-treatment","title":{"rendered":"FDA OKs Nucala for \u2018Smoker\u2019s Lung\u2019 Treatment"},"content":{"rendered":"<p data-start=\"148\" data-end=\"575\"><strong data-start=\"148\" data-end=\"162\">ISLAMABAD:<\/strong> The U.S. Food and Drug Administration (FDA) has granted approval for Nucala, an asthma medication developed by British pharmaceutical company GlaxoSmithKline (GSK), to be used as an additional treatment for patients suffering from chronic obstructive pulmonary disease (COPD), often referred to as \u201csmoker\u2019s lung.\u201d This decision was announced by GSK on Thursday, marking an expansion in the drug\u2019s approved uses.<\/p>\n<h2 data-start=\"577\" data-end=\"626\">Nucala\u2019s Mechanism and Clinical Trial Results<\/h2>\n<p data-start=\"628\" data-end=\"1199\">Nucala is a monoclonal antibody that targets interleukin-5, a protein involved in the regulation of eosinophils\u2014white blood cells that cause lung inflammation when present in excessive amounts.<\/p>\n<p data-start=\"628\" data-end=\"1199\">The approval was based on results from a late-stage clinical trial in which patients receiving Nucala alongside their regular inhaled maintenance therapy experienced a 21% reduction in disease exacerbations over 104 weeks, compared to those given a placebo.<\/p>\n<p data-start=\"628\" data-end=\"1199\">These exacerbations often lead to hospitalizations, which the drug aims to reduce to improve patients\u2019 quality of life.<\/p>\n<h2 data-start=\"1201\" data-end=\"1232\">Context and Market Position<\/h2>\n<p data-start=\"1234\" data-end=\"1603\">Nucala joins other approved treatments for COPD, including Sanofi and Regeneron\u2019s Dupixent and Verona Pharma\u2019s inhaled therapy Ohtuvayre.<\/p>\n<p data-start=\"1234\" data-end=\"1603\">The chronic lung condition primarily affects smokers but can also result from exposure to air pollution and occupational hazards. According to the World Health Organization, COPD ranks as the fourth leading cause of death globally.<\/p>\n<p data-start=\"1605\" data-end=\"1914\">Despite the FDA missing its initially set target date for the approval, this decision is a significant development in the management of a disease with a high global burden.<\/p>\n<p data-start=\"1605\" data-end=\"1914\">Nucala generated sales worth \u00a31.78 billion (approximately $2.38 billion) last year, underscoring its importance in respiratory medicine.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ISLAMABAD: The U.S. Food and Drug Administration (FDA) has granted approval for Nucala, an asthma medication developed by British pharmaceutical company GlaxoSmithKline (GSK), to be used as an additional treatment for patients suffering from chronic obstructive pulmonary disease (COPD), often referred to as \u201csmoker\u2019s lung.\u201d This decision was announced by GSK on Thursday, marking an &hellip;<\/p>\n","protected":false},"author":6,"featured_media":1320,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[415,414,413,412,416],"class_list":["post-1319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-copd","tag-fda-approval","tag-gsk","tag-nucala","tag-smokers-lung"],"_links":{"self":[{"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/posts\/1319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/comments?post=1319"}],"version-history":[{"count":1,"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/posts\/1319\/revisions"}],"predecessor-version":[{"id":1321,"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/posts\/1319\/revisions\/1321"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/media\/1320"}],"wp:attachment":[{"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/media?parent=1319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/categories?post=1319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/youdigital.pk\/en\/wp-json\/wp\/v2\/tags?post=1319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}